Ala-Houhala Meri J, Vähävihu Katja, Hasan Taina, Kautiainen Hannu, Snellman Erna, Karisola Piia, Dombrowski Yvonne, Schauber Jürgen, Saha Heikki, Reunala Timo
Department of Dermatology, Tampere University Hospital, Tampere, Finland.
Nephrol Dial Transplant. 2012 Jun;27(6):2435-40. doi: 10.1093/ndt/gfr700. Epub 2011 Dec 15.
Chronic kidney disease (CKD) patients are especially prone to vitamin D insufficiency. Narrow-band ultraviolet B (NB-UVB) treatment increases serum 25-hydroxyvitamin D [25(OH)D] in dermatological patients, and we studied whether it also improves vitamin D balance in CKD patients on haemodialysis.
Fifteen dialysis patients (mean age 48.3 years) and 12 healthy subjects (mean age 43.6 years) received nine NB-UVB exposures on the upper body. Serum 25(OH)D and 1,25(OH)(2)D were measured before and after the exposures. From skin biopsy specimen messenger RNA (mRNA) expression levels of CYP24A1 and CYP27B1, two enzymes needed for hydroxylation of vitamin D into its active metabolites, and of antimicrobial peptide cathelicidin, were examined.
Before NB-UVB, mean serum 25(OH)D was 32.5 ± 10.2 nmol/L in the dialysis patients and 60.2 ± 18.0 nmol/L in the healthy subjects (P < 0.001). After eight NB-UVB exposures, serum 25(OH)D increased by 13.8 nmol/L (43%; P < 0.001) and serum 1,25(OH)(2)D by 3.3 pmol/L (27%; P = 0.002) in the dialysis patients. After NB-UVB exposures, CYP27B1 mRNA was increased (P = 0.04), whereas cathelicidin mRNA was decreased (P < 0.0001) compared to non-treated healthy subjects. One and 2 months after NB-UVB exposure, serum 25(OH)D was still 10% higher than initially in the dialysis patients.
The present study shows that a short course of NB-UVB exposure increases significantly serum 25(OH)D and 1,25(OH)(2)D in dialysis patients. The effect is, however, short lasting suggesting that the patients need cyclic NB-UVB exposure to maintain their improved vitamin D concentration.
慢性肾脏病(CKD)患者尤其容易出现维生素D缺乏。窄谱中波紫外线(NB-UVB)治疗可提高皮肤病患者的血清25-羟基维生素D[25(OH)D]水平,我们研究了其是否也能改善血液透析的CKD患者的维生素D平衡。
15例透析患者(平均年龄48.3岁)和12名健康受试者(平均年龄43.6岁)接受了9次上身NB-UVB照射。在照射前后检测血清25(OH)D和1,25(OH)₂D水平。从皮肤活检标本中检测维生素D羟化生成其活性代谢产物所需的两种酶CYP24A1和CYP27B1以及抗菌肽cathelicidin的信使核糖核酸(mRNA)表达水平。
在NB-UVB照射前,透析患者的血清25(OH)D平均水平为32.5±10.2nmol/L,健康受试者为60.2±18.0nmol/L(P<0.001)。在接受8次NB-UVB照射后,透析患者的血清25(OH)D升高了13.8nmol/L(43%;P<0.001),血清1,25(OH)₂D升高了3.3pmol/L(27%;P=0.002)。与未接受治疗的健康受试者相比,NB-UVB照射后,CYP27B1 mRNA增加(P=0.04)而cathelicidin mRNA减少(P<0.0001)。在NB-UVB照射后1个月和2个月,透析患者的血清25(OH)D仍比最初水平高10%。
本研究表明,短期的NB-UVB照射可显著提高透析患者的血清25(OH)D和1,25(OH)₂D水平。然而,这种效果持续时间较短,提示患者需要周期性的NB-UVB照射以维持改善后的维生素D浓度。